Future medicines

Industry
By
Ruth Cooper
-

References

  1. Royal Australian College of General Practitioners. Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. 2024. At: www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/osteoporosis/pharmacologic-approaches-to-prevention/denosumab  
  2. NPS Medicinewise. Leqvio. 2023. www.nps.org.au/medicine-finder/leqvio 
  3. US Food and Drug Administration. FDA approves treatment for adults with Alzheimer’s disease. 2024. At: www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease 
  4. Bateman RJ, Li Y, McDade E, et al. Amyloid reduction and dementia progression in dominantly inherited Alzheimer’s disease after long-term gantenerumab treatment: results from the Dian-Tu trial. Lancet 2024. Epub 2024 Jul 26. 
  5. Lay, K. HIV drug could be made for just $40 a year for every patient. The Guardian. 2024. At: www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing 
  6. International AIDS Society. Statement from IAS President Sharon Lewin on full results from PURPOSE 1 trial of twice-yearly injectable lenacapavir for HIV prevention. 2024. At: www.iasociety.org/news-release/statement-ias-president-sharon-lewin-full-results-purpose-1-trial-twice-yearly  
  7. Ellis CR, Azmat CE. StatPearls. Adalimumab. 2023. At: www.ncbi.nlm.nih.gov/books/NBK557889/ 
  8. NPS Medicinewise. Androderm. 2020. www.nps.org.au/medicine-finder/androderm-transdermal-patch 
  9. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Trans Androl Urol 2016;5(6):834–43. 
  10. Gonzalez M. Recent trends and developments in injectable drug formulation and delivery. ONdrugDelivery. 2022;133:16–18. At: www.ondrugdelivery.com/recent-trends-and-developments-in-injectable-drug-formulation-delivery/ 
  11. World Health Organization. Adherence to long-term therapies: evidence for action. 2003. At: iris.who.int/handle/10665/42682  
  12. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4): 304–314. At: www.ncbi.nlm.nih.gov/pmc/articles/PMC3068890/ 
  13. Mandavilli A. Long-acting drugs may revolutionize HIV prevention and treatment. The New York Times. 2024. At: www.nytimes.com/2024/04/17/health/hiv-long-acting-shots-pills.html 
  14. ACON. Long-acting injectables for HIV treatment and prevention. 2021. At: https://www.acon.org.au/wp-content/uploads/2021/08/2021-08-20-ACON-Long-acting-injectables-for-HIV-treatment-and-prevention-.pdf   
  15. ASHM. Long-acting injectable HIV treatment tool. ashm.org.au/wp-content/uploads/2024/08/ASHM-Long-Acting-Injectable-HIV-Treatment-Tool-Aug24.pdf 
  16. ASHM. Implementing long-acting injectable HIV pre-exposure prophylaxis using Cabotegravir-LA: recommendations to support the Australian health sector. 2024. At: ashm.org.au/wp-content/uploads/2024/09/Implementing-long-acting-injectable-HIV-pre-exposure-prophylaxis-using-Cabotegravir-LA_2024_Summary-Report.Final_.pdf 
  17. AVAC. Second pivotal trial of twice-yearly HIV prevention injection safe and highly effective: PURPOSE 2 trial among gay men, trans and nonbinary people. 2024. At: avac.org/press-release/purpose-2/